32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments
Improvement Reflects Strict Expense Control and 17% U.S. Sales Growth1
Finalization of Safeguard Plan, including Restructuring of Existing Bank Debt, Planned Equity Capital Raise, and Expected Allocation of Free Warrants to all Shareholders
Webinar for shareholders and investors – Monday, October 6, 2025, at 6:00 PM CEST Registration Link
Paris and Boston, October 1st, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its unaudited financial results for the first half of 2025 and provides a business update.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “At no time since our 2011 IPO has Mauna Kea been at such a strategic crossroads. The Safeguard Procedure we entered voluntary earlier this year has been exceedingly demanding to navigate. However, the process has evidenced the organization’s resolve to both increase its operational efficiency and ensure that the clinical value of Cellvizio reaches patients and health providers. For example, in the first half of 2025 we reduced our current operating loss by 32% (before non-cash share-based payments). In the same period, outstanding execution by our newly revamped US sales team, when combined with the strength of Cellvizio’s value proposition in the fields of pancreatic cysts, Barrett’s Esophagus and food intolerance, delivered 17% sales growth (in constant exchange rate), perfectly in line with our business plan. We also welcome the commitment of our employees, as evidenced by the stability of our organization in France. While recent performance in Europe and China has lagged, the past 6-months has provided us a greater understanding of the levers available to meet our performance objectives. We look forward to concluding our financial restructuring and to authoring a renewed cycle of growth and profitability.”
1 In USD
